Current oligonucleotide manufacturing processes are unsustainable for future demand - GemBio aims to build what conventional processes can’t.
What does the future of therapeutics look like?
At GemBio, we believe it lies in oligonucleotide therapies, and we're building a reimagined manufacturing process to power it.
GemBio is transforming oligonucleotide production with a scalable, high-purity, and sustainable manufacturing platform to meet growing demand for both approved and future oligonucleotide therapeutics.
Our proprietary purification and manufacturing technology ensures consistent, commercial-grade oligonucleotides from research to clinical production, eliminating CMC variability. By improving efficiency and reducing manufacturing costs, GemBio aims to set new industry standards, empowering our partners to deliver breakthrough therapies to patients with greater speed and reliability.
